Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: rooney c. NPJ Breast Cancer. 2023 Aug 5;9(1):64. doi: 10.1038/s41523-023-00571-w. NPJ Breast Cancer. 2023. PMID: 37543694 Free PMC article.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, DeBruin E, Barry ST. Hopcroft L, et al. Among authors: rooney c. NPJ Breast Cancer. 2023 Aug 18;9(1):69. doi: 10.1038/s41523-023-00575-6. NPJ Breast Cancer. 2023. PMID: 37596288 Free PMC article. No abstract available.
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.
Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S, Bradshaw L, Blaker C, Gunda S, Owenson V, Hoffmann S, Sutton D, Jones S, Goodwin RJA, Willis BS, Rooney C, de Bruin EC, Barry ST. Hopcroft L, et al. Among authors: rooney c. NPJ Breast Cancer. 2023 Sep 19;9(1):76. doi: 10.1038/s41523-023-00581-8. NPJ Breast Cancer. 2023. PMID: 37726304 Free PMC article. No abstract available.
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Eberlein C, Williamson SC, Hopcroft L, Ros S, Moss JI, Kerr J, van Weerden WM, de Bruin EC, Dunn S, Willis B, Ross SJ, Rooney C, Barry ST. Eberlein C, et al. Among authors: rooney c. Br J Cancer. 2024 May;130(8):1377-1387. doi: 10.1038/s41416-024-02614-w. Epub 2024 Feb 23. Br J Cancer. 2024. PMID: 38396173 Free PMC article.
540 results